Novo nordisk takes actions to help protect us patients from unlawful sales of non-fda approved medicines claiming to contain semaglutide

Initiating legal proceedings against medical spas, weight loss or wellness clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and unlawful sales informing the public on how to identify novo nordisk's authentic semaglutide injectable products in the us providing semaglutide.com as resource hub and credible source of information in line with company's commitment to responsible use of our medicines and patient safety plainsboro, n.j. , june 20, 2023 /prnewswire/ -- novo nordisk announced today that it is taking multiple actions to protect us patients from the unlawful marketing and sales of non-fda approved counterfeit and compounded semaglutide products claiming to contain semaglutide, while reinforcing the responsible use of novo nordisk's fda-approved medicines.
NVO Ratings Summary
NVO Quant Ranking